Abstract:
BACKGROUND:Recent evidence indicates that atypical antipsychotics represent a promising option for the treatment of autistic disorder. In particular, risperidone appears to be effective in treating aggressiveness, hyperactivity, irritability, stereotypies, social withdrawal, and lack of interests. OBJECTIVE:The aim of the present study was to evaluate the effectiveness and tolerability of risperidone in children with autistic disorder and to examine the correlation between plasma levels of risperidone and its active metabolite 9-hydroxyrisperidone (9-OH-risperidone) and the clinical response. METHODS:The effect of treatment with risperidone (0.75-2 mg/day; mean +/- SD dose = 1.26 +/- 0.42 mg/day) was studied for 24 weeks in 20 children (14 boys, 6 girls) ages 3 to 10 years (mean age 6.0 +/- 2.4 years), diagnosed with autistic disorder. Fourteen items selected from the Children's Psychiatric Rating Scale (CPRS-14) and Clinical Global Impression (CGI) were used for behavioral evaluation. Patients were classified as responders if they showed a 25% or greater decrease on CPRS-14 total score at final evaluation compared with baseline and a final CGI rating of 1 or 2. Patients were rated for extrapyramidal side effects on the Abnormal Involuntary Movement Scale (AIMS). Other side effects, including the expected side effects of atypical antipsychotics drugs, were assessed by a checklist. Blood samples for determination of risperidone and its active metabolite 9-OH-risperidone were obtained after 12 weeks, and serum prolactin levels were measured on admission and at weeks 12 and 24. RESULTS:The psychopathological state, as assessed by CPRS, improved significantly over the duration of treatment. The mean CPRS-14 scores decreased significantly from 63.7 +/- 10.0 at baseline to 52.9 +/- 14.3 at week 12 (p < 0.01). At the end of 12 weeks of treatment, 8 patients were considered responders, and 10 patients reached a minimal improvement. No further improvement was observed in the following 12 weeks. In all children, serum prolactin levels increased significantly (p < 0.001) from 166 +/- 88 UI/mL at baseline to 504 +/- 207 UI/mL at week 12 of risperidone treatment. Weight gain and increased appetite were the most common unwanted effects. A mean increase of 3.7 +/- 1.7 kg in body weight was observed at final evaluation as compared with baseline. There was no significant correlation between percent improvement in total CPRS score and the plasma level of risperidone's active fractions (the sum of the risperidone and 9-OH-risperidone plasma concentration). CONCLUSIONS:This study provides further evidence of the beneficial effects of risperidone in children diagnosed with autistic disorder. However, the potential advantages of risperidone should be weighed against the risk of unwanted effects, such as an increase in serum prolactin levels and weight gain. No relation was observed between total plasma risperidone and 9-OH-risperidone concentrations and clinical response.
journal_name
J Child Adolesc Psychopharmacoljournal_title
Journal of child and adolescent psychopharmacologyauthors
Gagliano A,Germanò E,Pustorino G,Impallomeni C,D'Arrigo C,Calamoneri F,Spina Edoi
10.1089/104454604773840472keywords:
subject
Has Abstractpub_date
2004-04-01 00:00:00pages
39-47issue
1eissn
1044-5463issn
1557-8992journal_volume
14pub_type
临床试验,杂志文章abstract:OBJECTIVES:The purpose of this study was to assess long-term improvement in quality of life (QOL) in adolescents with attention-deficit/hyperactivity disorder (ADHD) treated with lisdexamfetamine dimesylate (LDX). METHODS:Adolescents with ADHD treated for ≥3 weeks in a 4 week, placebo-controlled study entered a 1 year...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1089/cap.2013.0077
更新日期:2014-05-01 00:00:00
abstract:OBJECTIVE:To assess the effect of Osmotic-Release Oral System (OROS) methylphenidate (MPH) on a variety of measures evaluating academic performance, cognition, and social behavior in children with attention-deficit/hyperactivity disorder (ADHD). METHODS:This double-blind, randomized, placebo-controlled, crossover labo...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1089/cap.2010.0047
更新日期:2011-04-01 00:00:00
abstract:: Objective: To explore blinded observational outcomes in the Treatment of Severe Childhood Aggression (TOSCA) study. Methods: During a 9-week acute trial, children with severe physical aggression and attention-deficit/hyperactiv...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章
doi:10.1089/cap.2019.0109
更新日期:2020-02-01 00:00:00
abstract:BACKGROUND:Prior studies have suggested that inhibited temperament may be associated with an increased risk for developing anxiety or mood disorder, including bipolar disorder. However, the neurobiological basis for this increased risk is unknown. The aim of this study was to examine temperament in symptomatic and asym...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章
doi:10.1089/cap.2016.0086
更新日期:2017-04-01 00:00:00
abstract:OBJECTIVE:To examine the basal thyroid function in pediatric Obsessive Compulsive Disorder (OCD) versus controls, and to explore the relation between baseline thyroid measures and response to clomipramine treatment, and the effects of treatment on thyroid hormones. METHODS:Sixteen children and adolescents with DSM-III...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 临床试验,杂志文章
doi:10.1089/cap.2005.15.581
更新日期:2005-08-01 00:00:00
abstract:OBJECTIVE:The use of methylphenidate (MPH) in the treatment of attention-deficit/hyperactivity disorder (ADHD) is widely accepted; however, there is increased concern regarding its abuse potential. Few studies have examined the reinforcing effects of drugs in individuals receiving them for clinical purposes. This study...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 临床试验,杂志文章
doi:10.1089/cap.2005.15.729
更新日期:2005-10-01 00:00:00
abstract:OBJECTIVE:The aim of this study was to compare the pharmacokinetics of immediate-release methylphenidate (MPH) in preschool and school-aged children with attention-deficit/hyperactivity disorder (ADHD). METHODS:Preschool children 4-5 years (n = 14) and school-aged children 6-8 years (n = 9) with diagnoses of ADHD were...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 临床试验,杂志文章
doi:10.1089/cap.2007.0043
更新日期:2007-04-01 00:00:00
abstract:INTRODUCTION:The antipsychotic drugs are the best-studied agents shown to reduce symptoms in autism, including hyperactivity, aggression, self-abusive behavior, temper tantrums, lability, irritability, social withdrawal, and stereotypical behaviors. However, significant weight gain has been associated with use of many ...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章
doi:10.1089/cap.2006.0126
更新日期:2007-12-01 00:00:00
abstract::The selective serotonin reuptake inhibitors (SSRIs) are becoming widely used in children and adolescents, with possible unexpected side effects being observed over time. SSRIs have been associated with bleeding in adults who have unremarkable routine hematologic laboratory results except abnormal bleeding time or plat...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章
doi:10.1089/cap.2000.10.35
更新日期:2000-04-01 00:00:00
abstract::Risperidone has been shown to improve serious behavioral problems in children with autism. Here we asked whether risperidone-associated improvement was related to changes in concentrations of inflammatory molecules in the serum of these subjects. Seven molecules were identified as worthy of further assessment by perfo...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章
doi:10.1089/cap.2010.0134
更新日期:2011-12-01 00:00:00
abstract:OBJECTIVE:This study aimed to compare the depression and burnout levels of mothers of children having attention-deficit/hyperactivity disorder (ADHD) between the child's pre- and posttreatment periods. METHOD:The study sample consisted of 40 children aged between 4 and 10 years and their mothers. Initially, 40 cases p...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章
doi:10.1089/cap.2017.0050
更新日期:2018-06-01 00:00:00
abstract:OBJECTIVE:The aim of this study was to examine immediate-release methylphenidate effectiveness during the 10-month open-label continuation phase of the Preschoolers with Attention-Deficit/Hyperactivity Disorder (ADHD) Treatment Study (PATS). METHODS:One hundred and forty preschoolers with ADHD, who had improved with a...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章
doi:10.1089/cap.2007.0058
更新日期:2007-10-01 00:00:00
abstract::ABSTRACT The sudden collapse and death in three prepubertal children during routine treatment with desipramine was recently reported in brief statements. Insufficient clinical information is available to infer a cause-and-effect relationship between the therapeutic use of desipramine and sudden death in these children...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章
doi:10.1089/cap.1990.1.125
更新日期:1990-10-01 00:00:00
abstract::ABSTRACT The pertinent literature was reviewed on cardiovascular changes induced by psychostimulant medication treatment of hyperactive children. An assessment of 15 controlled studies using test doses of methylphenidate revealed a significant elevation of the resting heart rate in previously unmedicated children (mea...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章
doi:10.1089/cap.1992.2.279
更新日期:1992-01-01 00:00:00
abstract::This open-label study examined the potential efficacy of paroxetine in the treatment of children and adolescents diagnosed with dysthymia over a period of 3 months. Seven subjects were evaluated by the Hamilton Depression Rating Scale (HAM-D), by the Clinical Global Impression Severity of Illness Scale (CGI-S), and th...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 临床试验,杂志文章
doi:10.1089/cap.2000.10.103
更新日期:2000-07-01 00:00:00
abstract:OBJECTIVE:The aim of this study was to analyze changes in the prevalence and incidence of antidepressant use among children and adolescents in Finland post October, 2003. METHOD:The sample comprised all children and adolescents in Finland aged < or =19.0 years (n = 27,676) who collected one or more reimbursed prescrip...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章
doi:10.1089/cap.2009.0040
更新日期:2010-04-01 00:00:00
abstract::Although sensory deficits are frequently observed in autistic individuals, pharmacologic interventions targeting these abnormalities are lacking. The goal of this investigation was to assess the effectiveness of aripiprazole in targeting sensory deficits in children and adolescents with autism. Using an outpatient cli...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章
doi:10.1089/cap.2010.0103
更新日期:2012-06-01 00:00:00
abstract::The neuroanatomical model involved in the pathophysiology of obsessive-compulsive disorder (OCD) postulates a hyperactivation of orbitofrontal, limbic, and basal ganglia circuits. We report a case of OCD secondary to brain dysgerminoma affecting this circuit in an adolescent who responded to citalopram. The patient is...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章
doi:10.1089/104454602760386950
更新日期:2002-10-01 00:00:00
abstract:OBJECTIVE:The present study examined the course of ADHD over 24 months in a preschool population. METHOD:n=48 preschoolers with ADHD, aged 3.0-5.11 years, subjects included in a larger sample of preschoolers with depression and other disorders (n=306) were comprehensively assessed at 3 annual time points over 24 month...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章
doi:10.1089/cap.2010.0045
更新日期:2011-08-01 00:00:00
abstract:OBJECTIVE:The purpose of this article was to systematically review the literature on stimulant and atomoxetine combination therapy, in particular: 1) Characteristics of patients with attention-deficit/hyperactivity disorder (ADHD) given combination therapy, 2) treatment strategies used, 3) efficacy and effectiveness, a...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章,评审
doi:10.1089/cap.2012.0093
更新日期:2013-04-01 00:00:00
abstract:OBJECTIVE:Co-occurrence of substance use and bipolar disorders is both common and associated with poor treatment response and greater functional impairment than either disorder alone. The neurophysiological correlates of this co-morbidity however, remain unclear. In this pilot study, we compared brain morphometry betwe...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章
doi:10.1089/cap.2008.033
更新日期:2008-12-01 00:00:00
abstract:OBJECTIVE:The aim of this study was to examine the association between the CYP2D6 and CYP2C19 genotype-predicted combined phenotypes and short-term measures of psychotropic efficacy and toxicity. METHODS:A rater-blinded, retrospective genotype association design examined a cohort of hospitalized pediatric psychiatric ...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章
doi:10.1089/cap.2008.0103
更新日期:2009-08-01 00:00:00
abstract:OBJECTIVE:The purpose of this study was to investigate the preliminary effectiveness and safety of lamotrigine for the treatment of depressive episodes in adolescents. METHODS:This was a 12 week retrospective chart review of lamotrigine treatment among 37 adolescents (mean age 16.3±1.3 years) with depressive episodes ...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章
doi:10.1089/cap.2013.0121
更新日期:2014-06-01 00:00:00
abstract::A preliminary clinical observation suggests the possibility of changes in valproate level when coadministered with guanfacine. Two pediatric inpatients (8 and 9 years of age) were treated with valproic acid and guanfacine concurrently. In one child, when guanfacine was tapered and discontinued, the plasma valproate co...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 临床试验,杂志文章
doi:10.1089/cap.1998.8.143
更新日期:1998-01-01 00:00:00
abstract:BACKGROUND:Still little is known about neuropsychological differences between boys and girls with attention-deficit/hyperactivity disorder (ADHD) and whether there are sex-specific differences in the modulation of attentional performance by methylphenidate (MPH). METHOD:In this study, 27 males and 27 females between 8...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章,随机对照试验
doi:10.1089/cap.2009.0060
更新日期:2010-06-01 00:00:00
abstract:OBJECTIVE:Evening-dosed HLD200 is a delayed-release and extended-release methylphenidate (DR/ER-MPH) formulation consisting of uniform, dual-layered microbeads with an inner drug-loaded core. DR/ER-MPH is designed to delay the initial release of drug by 8-10 hours, and thereafter, provide a controlled, extended drug re...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1089/cap.2017.0084
更新日期:2017-08-01 00:00:00
abstract:OBJECTIVE:The aim of this study was to present the reliability and validity of the Children's Depression Rating Scale-Revised (CDRS-R) in the adolescent age group. METHOD:Adolescents with symptoms of depression were assessed using the CDRS-R and global severity and functioning scales at screening, baseline, and after ...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章
doi:10.1089/cap.2010.0063
更新日期:2010-12-01 00:00:00
abstract:BACKGROUND:Despite the increased recognition of attention deficit hyperactivity disorder (ADHD) in adolescents, few controlled studies have assessed treatments for this age group. Adolescent issues, such as embarrassment at receiving medication at school and experimentation with abusable substances, have accelerated ef...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1089/10445460050167313
更新日期:2000-10-01 00:00:00
abstract::Autism spectrum disorder (ASD) is commonly associated with a host of challenging behaviors. Pharmacotherapy is indicated if psychosocial and educational interventions fail. Atypical antipsychotics have the strongest evidence base so far, with both risperidone and aripiprazole being FDA approved. Unfortunately, their u...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章
doi:10.1089/cap.2016.0182
更新日期:2017-06-01 00:00:00
abstract:OBJECTIVE:The aim of this study was to summarize results of a blinded review of potential suicidal events and analyses comparing incidence rates between paroxetine- and placebo-treated pediatric patients. METHOD:One thousand one hundred ninety-one (1191) children and adolescents received paroxetine (n = 642) or placeb...
journal_title:Journal of child and adolescent psychopharmacology
pub_type: 杂志文章,评审
doi:10.1089/cap.2006.16.77
更新日期:2006-02-01 00:00:00